Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock

InvestingDec 16 06:14 ET

Express News | Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy

BenzingaDec 12 10:43 ET

Apogee Therapeutics Advances Phase 1 Clinical Trial for APG333 in Asthma and COPD With Interim Data Expected in 2H 2025

Quiver QuantitativeDec 10 07:12 ET

Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

ReutersDec 10 07:00 ET

Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

ReutersDec 10 07:00 ET

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

GlobeNewswireDec 10 07:00 ET